Publication:
Effects of centrally-injected glucagon-like peptide-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat

dc.contributor.buuauthorGüleç Süyen, Güldal
dc.contributor.buuauthorİşbil Büyükcoşkun, Naciye
dc.contributor.buuauthorKahveci, Nevzat
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentFizyoloji Ana Bilim Dalı
dc.contributor.orcid0000-0003-0863-1547
dc.contributor.orcid0000-0003-0841-8201
dc.contributor.researcheridAAH-1692-2021
dc.contributor.researcheridAAG-7070-2021
dc.contributor.researcheridC-5730-2015
dc.contributor.scopusid6602752303
dc.contributor.scopusid55665951400
dc.contributor.scopusid6602597846
dc.date.accessioned2022-01-14T07:32:22Z
dc.date.available2022-01-14T07:32:22Z
dc.date.issued2010-08
dc.description.abstractGlucagon-like peptide-1 (7-36)-amide (GLP-1) is a gut peptide, which exerts significant effects on glucose homeostasis. GLP-1 and GLP-1 receptors are also widely distributed in the central nervous system. In the present study, we aimed to investigate the effects of intracerebroventricularly (i.c.v.)-injected GLP-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat. Rats were pretreated with GLP-1 (1-1000 ng/5 mu l: i.c.v.) or saline (5 mu l; i.c.v.) 30 min before seizure induction by pilocarpine (2.4 mg/5 mu l; i.c.v.) and with GLP-1 (1, 10, 100 ng/5 mu l; i.c.v.) or saline (5 mu l; i.c.v.) 30 min before the open field test or the elevated plus maze test. GLP-1 did not produce any protective effect against pilocarpine-induced seizures and did not also produce statistically significant differences in the number of squares visited (measure of locomotor activity) or number of rearings (measure of exploratory behaviour), compared to the saline-treated rats in the open field test. On the other hand, GLP-1 (1 ng and 10 ng; icy.) induced an anxiogenic effect, indicated by a decrease in the time spent in open arms, an increase in the time spent in closed arms, and a decrease in the anxiety scores in the elevated plus maze test. Pretreatment with an arginine vasopressin (AVP) V(1) receptor antagonist (125 ng/5 mu l; i.c.v.) and L-NAME (100 mu g/5 mu l and 200 mu g/5 mu l) significantly abolished the anxiogenic effect of GLP-1 (1 ng/5 mu l; i.c.v.). These results suggest that, centrally-injected GLP-1 produces anxiogenic effects via NO pathway and AVP V(1) receptors, but does not have any effects on pilocarpine-induced seizures or locomotor and exploratory activity in the open field test.
dc.identifier.citationGüleç, G. vd. (2010). "Effects of centrally-injected glucagon-like peptide-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat". Neuropeptides, 44(4), 285-291.
dc.identifier.endpage291
dc.identifier.issn0143-4179
dc.identifier.issue4
dc.identifier.pubmed20227110
dc.identifier.scopus2-s2.0-77953536456
dc.identifier.startpage285
dc.identifier.urihttps://doi.org/10.1016/j.npep.2010.02.002
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0143417910000260
dc.identifier.urihttp://hdl.handle.net/11452/24096
dc.identifier.volume44
dc.identifier.wos000279098900001
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherChurchill Livingstone
dc.relation.journalNeuropeptides
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGLP-1
dc.subjectSeizure
dc.subjectOpen field
dc.subjectElevated plus maze
dc.subjectArginine vasopressin
dc.subjectNitric oxide
dc.subjectRat
dc.subjectHippocampal plasticity
dc.subjectReceptor
dc.subjectBrain
dc.subjectNeurons
dc.subjectVasopressin
dc.subjectExpression
dc.subjectExendin-4
dc.subjectRelease
dc.subjectNuclei
dc.subjectEndocrinology & metabolism
dc.subjectNeurosciences & neurology
dc.subject.emtreeArgipressin
dc.subject.emtreeGlucagon like peptide
dc.subject.emtreeN(g) nitroarginine methyl ester
dc.subject.emtreeNitric oxide
dc.subject.emtreePilocarpine
dc.subject.emtreeSodium chloride
dc.subject.emtreeVasopressin receptor antagonist
dc.subject.emtreeAnimal behavior
dc.subject.emtreeAnimal experiment
dc.subject.emtreeAnimal model
dc.subject.emtreeAnxiety
dc.subject.emtreeArticle
dc.subject.emtreeControlled study
dc.subject.emtreeDrug administration route
dc.subject.emtreeDrug efficacy
dc.subject.emtreeExploratory behavior
dc.subject.emtreeLocomotion
dc.subject.emtreeMale
dc.subject.emtreeMaze test
dc.subject.emtreeNeuroprotection
dc.subject.emtreeNonhuman
dc.subject.emtreeOpen field behavior
dc.subject.emtreePriority journal
dc.subject.emtreeRat
dc.subject.emtreeResponse time
dc.subject.emtreeSeizure
dc.subject.emtreeTranquilizing activity
dc.subject.meshAnimals
dc.subject.meshAnti-anxiety agents
dc.subject.meshAnticonvulsants
dc.subject.meshAnxiety
dc.subject.meshExploratory behavior
dc.subject.meshGlucagon-like peptide 1
dc.subject.meshInjections, intraventricular
dc.subject.meshMale
dc.subject.meshMotor activity
dc.subject.meshMuscarinic agonists
dc.subject.meshNG-nitroarginine methyl ester
dc.subject.meshNitric oxide
dc.subject.meshNitric oxide synthase type I
dc.subject.meshPilocarpine
dc.subject.meshRats
dc.subject.meshRats, sprague-dawley
dc.subject.meshReceptors, vasopressin
dc.subject.meshSeizures
dc.subject.meshVasopressins
dc.subject.scopusGlucagon-Like Peptide-1 Receptor; Gastric Inhibitory Polypeptide; Exendin (9-39)
dc.subject.wosEndocrinology & metabolism
dc.subject.wosNeurosciences
dc.titleEffects of centrally-injected glucagon-like peptide-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat
dc.typeArticle
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Fizyoloji Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: